Adverse Event Management

Cabozantinib Associated With Higher Rates of Certain AEs in Advanced Kidney Cancer

June 11, 2021

While cabozantinib exposure was not a predictor of progression-free survival, it was related to high rate of palmar-plantar plantar erythrodysesthesia and diarrhea in patients with advanced renal cell carcinoma who are given frontline cabozantinib plus nivolumab.

Bone-Protecting Agents Reduce Fracture Risk During Prostate Cancer Treatment

June 09, 2021

Men with asymptomatic or mildly symptomatic metastatic castration-resistant prostate cancer who are being treated with radium-223 (Xofigo) plus enzalutamide (Xtandi) can reduce their risk of fractures with the use of bone-protecting agents.